Literature DB >> 11500255

Impact of cortisol on buspirone stimulated prolactin release: a double-blind placebo-controlled study.

T G Dinan1, L V Scott, J Thakore, J Naesdal, P W Keeling.   

Abstract

Buspirone is known to stimulate prolactin release. Clinical studies (e.g. in chronic fatigue syndrome) suggest that the response may be influenced by baseline cortisol levels. We conducted a double-blind placebo-controlled study to examine the relationship between the prolactin response to buspirone challenge and baseline cortisol level. Fifty healthy volunteers took part in the study. Buspirone was found to consistently elevate PRL levels above those seen following placebo administration. The PRL response as measured by area under the curve was highly correlated with the baseline cortisol level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500255     DOI: 10.1016/s0306-4530(01)00029-4

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  3 in total

1.  Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity.

Authors:  A M M Eijsbouts; F H J van den Hoogen; R F J M Laan; C G J Sweep; A R M M Hermus; L B A van de Putte
Journal:  Ann Rheum Dis       Date:  2004-08-19       Impact factor: 19.103

2.  Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.

Authors:  Kari Laine; Outi Ahokoski; Risto Huupponen; Jutta Hänninen; Sanna Palovaara; Jori Ruuskanen; Harry Björklund; Markku Anttila; Juha Rouru
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

Review 3.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.